Holen Sie sich die Stockscreener-App
77.03
1.31%
0.93
Schlusskurs vom Vortag:
$76.10
Offen:
$76.07
24-Stunden-Volumen:
101.65K
Relative Volume:
0.24
Marktkapitalisierung:
$1.73B
Einnahmen:
$747.40M
Nettoeinkommen (Verlust:
$-12.60M
KGV:
-100.21
EPS:
-0.7687
Netto-Cashflow:
$105.18M
1W Leistung:
+1.04%
1M Leistung:
-5.14%
6M Leistung:
-19.69%
1J Leistung:
+30.38%
1-Tages-Spanne:
$74.80
$77.20
1-Wochen-Bereich:
$72.43
$78.00
52-Wochen-Spanne:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
76.95 | 1.71B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
489.64 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Director at ANI Pharmaceuticals (ANIP) sells 6,000 shares - Stock Titan
SVP & CFO At ANI Pharmaceuticals Buys $1.72M of Stock - Benzinga
833K Reasons To Be Bullish On ANI Pharmaceuticals Stock - Benzinga
SVP Of ANI Pharmaceuticals Makes $1.00M Buy - Benzinga
SVP Of ANI Pharmaceuticals Purchased $464K In Stock - Benzinga
ANI Pharmaceuticals (ANIP) Stock Analysis: A Compelling 47% Upside Potential Awaits Investors - DirectorsTalk Interviews
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf. - Yahoo Finance
ANI Pharmaceuticals at Raymond James Conference: Rare Disease Focus By Investing.com - Investing.com Canada
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors - TipRanks
ANI Pharmaceuticals projects >$1B revenue in 2026, guides $275–$290M adjusted EBITDA - TradingView
ANI Pharmaceuticals : Corporate Presentation March 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ: ANIP) guides to over $1B in 2026 revenue - Stock Titan
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
ANI Pharmaceuticals (ANIP) SVP receives stock award, withholds shares for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) exec logs stock award and tax share disposal - Stock Titan
ANI Pharmaceuticals (ANIP) CEO logs restricted stock grant and tax-withholding share disposition - Stock Titan
ANI Pharmaceuticals (ANIP) SVP logs stock grant and tax withholding in Form 4 - Stock Titan
ANI Pharmaceuticals (ANIP) SVP reports stock award, tax withholding and LLC-held shares - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief reports stock award and tax withholding - Stock Titan
Restricted stock grant for ANI Pharmaceuticals (ANIP) general counsel - Stock Titan
ANI Pharmaceuticals (ANIP) CFO awarded restricted stock and has shares withheld for taxes - Stock Titan
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge (NASDAQ:ANIP) - Seeking Alpha
William Blair Investment Management LLC Sells 141,856 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quantbot Technologies LP Has $4.20 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)? - simplywall.st
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2025 Earnings Call Transcript - Insider Monkey
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4% - The Globe and Mail
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
ANI Pharma Q4 2025 slides: rare disease shift drives 44% revenue growth - Investing.com Australia
ALIM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Earnings call transcript: ANI Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com Nigeria
ANI Pharmaceuticals Inc (ANIP) Q4 2025 Earnings Call Highlights: Record Revenue and Strong ... By GuruFocus - Investing.com Canada
ANI Pharmaceuticals Reports Strong Q4 Earnings Growth - Intellectia AI
ANI Pharmaceuticals Reports Q4 Net Income Growth - Intellectia AI
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - Finviz
ANI Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIP) 2026-02-27 - Seeking Alpha
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - Finviz
ANI Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ANI Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript - The Globe and Mail
ANI Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% - Benzinga
ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth - TipRanks
ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ANI Pharmaceuticals (ANIP) Stock: Revenue Jumps 44% as Rare Disease Pipeline Transforms Outlook - CoinCentral
Ani Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
ANI PHARMACEUTICALS ($ANIP) Releases Q4 2025 Earnings - Quiver Quantitative
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):